派姆单抗在晚期头颈癌一线治疗中的应用

资源简介

派姆单抗在晚期头颈癌一线治疗中的应用

【数据集背景】

本数据集源站标题为《Pembrolizumab in the first-line treatment of advanced head and neck cancer》。配套论文《Pembrolizumab in the first-line treatment of advanced head and neck cancer》发表于 Expert Review of Anticancer Therapy（2021），DOI：10.1080/14737140.2021.1996228。项目资助方：The authors have no funding to report.。源站首次发布：2021-11-03。

【数据内容】

源站原始描述：Recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) is associated with dismal prognosis and has limited therapeutic options. PD-1/PD-L1 axis blockade was initially shown to improve outcomes in platinum-refractory HNSCC. More recently, pembrolizumab monotherapy or pembrolizumab combined with chemotherapy resulted in better overall survival than platinum, 5-fluorouracil, and cetuximab (EXTREME regimen) as first-line therapy for R/M HNSCC, establishing a new standard-of-care…

【数据结构与技术规格】

文件数 2 个，合计 230.53 KB。Sup_Table 1.docx：application/vnd.openxmlformats-officedocument.wordprocessingml.document，18.64 KB。Supplementary Fig 1.jpg：image/jpeg，211.89 KB。数据集 DOI：10.6084/m9.figshare.16920962.v1。

【主题与分类】

源站学科分类：Space Science、Medicine、Mathematical Sciences not elsewhere classified、Cancer、Science Policy。主题标签：Head and neck squamous cell carcinoma、immune checkpoint inhibitor、immunotherapy、palliative care、PD-1 inhibitor、pembrolizumab。

【适用方向】

源站学科分类标注为 Space Science、Medicine、Mathematical Sciences not elsewhere classified、Cancer、Science Policy。

【获取与许可】

源站页面：https://tandf.figshare.com/articles/dataset/Pembrolizumab_in_the_first-line_treatment_of_advanced_head_and_neck_cancer/16920962

使用许可：CC BY 4.0（https://creativecommons.org/licenses/by/4.0/）。

规范引用：Pembrolizumab in the first-line treatment of advanced head and neck cancer. Taylor & Francis. de Sousa, Luana Guimaraes; Ferrarotto, Renata

【使用注意】

· 源站最后修改于 2023-05-31，引用时请注意版本时效。